艾曲波帕对难治性原发免疫性血小板减少症的疗效及其对细胞免疫功能的影响

doi:10.5246/jcps.2023.09.060

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (9): 736-743.DOI: 10.5246/jcps.2023.09.060

艾曲波帕对难治性原发免疫性血小板减少症的疗效及其对细胞免疫功能的影响

杨晗春^*(), 成斐, 黄娟娟

三亚中心医院血液科, 海南 572000

收稿日期:2023-02-24 修回日期:2023-04-19 接受日期:2023-05-20 出版日期:2023-09-30 发布日期:2023-09-30
通讯作者: 杨晗春
作者简介:
+ Tel.: +86-13922165215, E-mail: Luzhun184@163.com

Efficacy of eltrombopag on refractory primary immune thrombocytopenia and its effect on cellular immune function

Hanchun Yang^*(), Fei Cheng, Juanjuan Huang

Department of Hematology, Sanya Central Hospital, Hainan 572000, China

Received:2023-02-24 Revised:2023-04-19 Accepted:2023-05-20 Online:2023-09-30 Published:2023-09-30
Contact: Hanchun Yang

摘要/Abstract

摘要：

探讨艾曲波帕在难治性原发免疫性血小板减少症(ITP)治疗中的临床效果及其对细胞免疫功能的影响。选取2019年1月至2022年10月我院收治的132例难治性ITP患者纳入研究, 将其分为联合治疗组(44例)、单一治疗组(44例)和对照组(44例), 联合治疗组给予艾曲波帕联合长春地辛治疗, 单一治疗组给予艾曲波帕单药治疗, 对照组仅给予生活方式干预治疗, 疗程均为12周。比较三组临床疗效及不良反应, 检测治疗前后三组血小板计数(PLT)、出血时间(BT)、T淋巴细胞亚群(CD₄⁺、CD₈⁺)、B淋巴细胞亚群(CD₁₉⁺、CD₂₀⁺)、Th1细胞因子(IFN-γ、IL-2)及Th2细胞因子(IL-5、IL-4)水平变化。治疗后, 单一治疗组完全反应率明显高于对照组, 联合治疗组完全反应率明显高于单一治疗组(均P < 0.05)。单一治疗组治疗总有效率高于对照组(P < 0.05); 联合治疗组总有效率高于单一治疗组(P < 0.05)。与对照组比较, 单一治疗组治疗后PLT及BT检测值均明显改善(P < 0.05); 与单一对照组比较, 联合治疗组治疗后PLT及BT检测值均明显改善(P < 0.05)。与对照组比较, 单一治疗组治疗后CD₄⁺/CD₈⁺及CD₁₉⁺/CD₂₀⁺均明显改善(P < 0.05); 与单一治疗组比较, 联合治疗组治疗后CD₄⁺/CD₈⁺及CD₁₉⁺/CD₂₀⁺均明显改善(P﹤0.05); 与对照组比较, 单一治疗组及联合治疗组治疗12周后血清IFN-γ、IL-2水平明显较低, 而血清IL-5、IL-4水平明显较高(P < 0.05); 与单一治疗组比较, 联合治疗组治疗12周后血清IFN-γ、IL-2水平明显较低, 而血清IL-5、IL-4水平明显较高(P < 0.05); 三组不良反应发生率比较无显著差异(P > 0.05)。对于难治性原发免疫性血小板减少症患者, 艾曲波帕与免疫抑制剂联合治疗安全有效, 利于细胞免疫功能恢复。

关键词: 原发免疫性血小板减少症, 艾曲波帕, 临床疗效, 细胞免疫功能

Abstract:

To investigate the clinical effects of eltrombopag in treating refractory primary immune thrombocytopenia (ITP) and its impact on cellular immune function, we selected 132 patients with refractory ITP admitted to our hospital between January 2019 and October 2022. They were divided into three groups: the combined treatment group (44 cases), the single treatment group (44 cases), and the complete control group (44 cases). The combined treatment group received etrapopa combined with vindesine, the single treatment group received eltrombopag, and the complete control group only received lifestyle intervention. The treatment course was 12 weeks. We compared the clinical efficacy and adverse reactions of the three groups and collected peripheral blood samples before and after treatment to detect changes in platelet count (PLT), bleeding time (BT), T lymphocyte subsets (CD₄⁺, CD₈⁺), B lymphocyte subsets (CD₁₉⁺, CD₂₀⁺), Th1 cytokines (IFN-γ, IL-2), and Th2 cytokines (IL-5, IL-4). After treatment, the complete response rate in the single treatment group was significantly higher than that in the complete control group, and the complete response rate in the combined treatment group was significantly higher than that in the single treatment group (both P < 0.05). The total effective rate in the combined treatment group was also higher than that in the single treatment group (P < 0.05). Compared with the complete control group, the PLT and BT values in the single treatment group were significantly improved after treatment (P < 0.05), and the combined treatment group had significantly improved PLT and BT values compared to the single treatment group (P < 0.05). The CD₄⁺/CD₈⁺ and CD₁₉⁺/CD₂₀⁺ values in the single treatment group were significantly improved after treatment compared with the complete control group (P < 0.05), and the combined treatment group showed significantly improved CD₄⁺/CD₈⁺ and CD₁₉⁺/CD₂₀⁺ values compared to the single treatment group (P < 0.05). Serum IFN-γ and IL-2 levels in the single and combined treatment groups were significantly lower than those in the complete control group after 12 weeks of treatment, while the levels of serum IL-5 and IL-4 were significantly higher (P < 0.05). The combined treatment group had significantly higher serum IL-5 and IL-4 levels than the single treatment group after 12 weeks of treatment (P < 0.05). The incidence of adverse reactions among the three groups was not significantly different (P > 0.05). In conclusion, for patients with refractory primary ITP, combined therapy of eltrombopag and immunosuppressants is safe and effective, improving cellular immune function.

Key words: Primary immune thrombocytopenia, Eltrombopag, Clinical efficacy, Cellular immune function

Supporting:

杨晗春, 成斐, 黄娟娟. 艾曲波帕对难治性原发免疫性血小板减少症的疗效及其对细胞免疫功能的影响[J]. 中国药学(英文版), 2023, 32(9): 736-743.

Hanchun Yang, Fei Cheng, Juanjuan Huang. Efficacy of eltrombopag on refractory primary immune thrombocytopenia and its effect on cellular immune function[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 736-743.

图/表 3

参考文献 19

[1]	LeVine, D.N.; Brooks, M.B. Immune thrombocytopenia (ITP): Pathophysiology update and diagnostic dilemmas. Vet. Clin. Pathol. 2019, 48, 17–28.
[2]	Onisâi, M.; Vlădăreanu, A.M.; Spînu, A.; Găman, M.; Bumbea, H. Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom. J. Intern. Med. 2019, 57, 273–283.
[3]	Hou, M.; Liu, X.G. Diagnosis and treatment of primary immune thrombocytopenia based on China’s actual situation -- Interpretation of the 2020 version of the Chinese guidelines for the diagnosis and treatment of adult primary immune thrombocytopenia. J. Clin. Hematol. 2021, 1, 6–9.
[4]	Abbinante, V.M.; Zampieri, M.; Barreca, G.; Masciocchi, N. Preparation and solid-state characterization of eltrombopag crystal phases. Molecules. 2020, 26, 65.
[5]	Sun, Y.H.; Ran, X.H.; Gao, M.; Yan, F.H.; Bian, Q.Y.; Xu, W.J.; Cui, J.Y. Clinical study of low-dose dexcitabine in the treatment of refractory recurrent primary immune thrombocytopenia in adults. J. Clin. Hematol. 2020, 6, 1324–1326.
[6]	Hemostasis and Thrombology Group, Hematology Branch, Chinese Medical Association. Chinese expert consensus on diagnosis and treatment of adult primary immune thrombocytopenia (2016 edition). Chin. J. Hematol. 2016, 2, 89–93.
[7]	Jimura, N.; Fujii, K.; Higashi, Y.; Kanekura, T. Idiopathic thrombocytopenic purpura in a patient with IgG4-related disease. Clin. Exp. Dermatol. 2018, 43, 941–943.
[8]	Castaneira, G.; Rojas, K.; Galili, Y.; Field, Z.; Perez-Perez, A.; Madruga, M.; Carlan, S.J. Idiopathic thrombocytopenic purpura induced by synthetic cannabinoid. J. Addict. Med. 2019, 13, 235–236.
[9]	Cooper, N.; Ghanima, W. Immune thrombocytopenia. N. Engl. J. Med. 2019, 381, 945–955.
[10]	Yao, S.Y.; Hu, X.J.; Lai, Y.C.; Jiang, Y.R.; Li, Z.K. Etripopal combined with low-dose rituximab in the treatment of a case of primary immune thrombocytopenia in the elderly with chronic diseases and literature review. Leu. Lymphoma. 2020, 5, 298–300.
[11]	Luo, H.Q.; Zhong, Y.G.; Feng, W.Y. Study on the efficacy of Etripopal combined with azathioprine in the treatment of refractory idiopathic thrombocytopenic purpura and its effect on cellular immune function. China Gen. Med. 2019, 21, 2588–2589.
[12]	Bai, H.C.; Feng, J.; Yuan, Z.T.; Wang, S.B. The clinical efficacy of low-dose rituximab combined with etrippa in the treatment of steroid-resistant ITP. West. Med. 2020, 4, 107–108.
[13]	Chen, T.; Gao, J.L. Effect of rhTPO combined with low-dose hormone on primary immune thrombocytopenia. China J. Matern. Child Health Care. 2020, 7, 1246–1248.
[14]	Ito, M.; Kanda, S.; Yoshida, T.; Okuma, Y.; Jo, H.; Fukuhara, S.; Maeshima, A.M.; Ohe, Y. Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient. Lung Cancer. 2020, 146, 362–365.
[15]	Xu, H.M.; Feng, J.S. Progress in the treatment of chronic primary immune thrombocytopenia in adults with biological agents. J. Guangdong Med. Coll. 2022, 1, 108–112.
[16]	Di, Z.X.; Geng, Y.; Sun, X.L.; Su, A.Y.; Guo, K.; Li, Q. The expression of CD₁₉⁺B cells in patients with immune thrombocytopenia and the role of serum Breg in the pathogenesis of patients. J. Exp. Hematol. 2019, 3, 911–915.
[17]	Cao, L.H.; Pan, Q.; Fan, C.H.; Wu, H.; Fu, L.S.; Fu, G.L.; Lin, Y.Q.; Lou, J.Y.; Yu, W.J.; Jin, J. Observation on the effect of Etripopal combined with cyclosporine A in the treatment of immune thrombocytopenia. Zhejiang Med. J. 2021, 9, 996–998+1002.
[18]	Jie, M.; Fu, L.L.; Li, S.D.; He, Y.X.; Yao, J.F.; Cheng, X.L.; Zhang, L.Q.; Zheng, J.; Zhang, R.; Wu, R.H. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children. Pediatr. Hematol. Oncol. 2021, 38, 647–657.
[19]	Cheng, X.L.; Fu, L.L.; Ma, J.Y.; Gu, H.; Chen, Z.P.; Zhao, L.B.; Wang, X.L.; Wu, R.H. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Adv. 2021, 5, 3799–3806.

艾曲波帕对难治性原发免疫性血小板减少症的疗效及其对细胞免疫功能的影响

Efficacy of eltrombopag on refractory primary immune thrombocytopenia and its effect on cellular immune function

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 19

相关文章 2

编辑推荐

Metrics

本文评价

[1]	袁叶, 李亚男, 赵晴, 于博, 杨秀岭. 基于PK/PD模型和蒙特卡洛模拟评价头孢曲松给药方案[J]. 中国药学(英文版), 2022, 31(5): 382-388.
[2]	林志燕, 田怀平, 李方, 秦丽萍, 张欣, 陆晓彤. 舒肝祛脂胶囊治疗成人单纯性肥胖的临床疗效及安全性评价[J]. 中国药学(英文版), 2017, 26(12): 890-894.